Uniqure (NASDAQ:QURE) Trading 6.1% Higher

Shares of Uniqure NV (NASDAQ:QURE) traded up 6.1% during trading on Tuesday . The stock traded as high as $56.42 and last traded at $56.24, 364,385 shares changed hands during trading. A decline of 39% from the average session volume of 596,297 shares. The stock had previously closed at $53.01.

Several analysts have recently commented on the company. Zacks Investment Research cut Uniqure from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. SunTrust Banks increased their target price on Uniqure to $76.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Guggenheim cut Uniqure from a “buy” rating to a “neutral” rating in a report on Monday, July 29th. BidaskClub cut Uniqure from a “sell” rating to a “strong sell” rating in a report on Thursday, August 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $94.00 target price (up previously from $81.00) on shares of Uniqure in a report on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $78.18.

The business’s fifty day moving average price is $67.47. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -24.03 and a beta of 0.94. The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.07 and a current ratio of 8.07.



Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.08). The firm had revenue of $2.47 million during the quarter, compared to the consensus estimate of $1.53 million. Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. On average, equities analysts predict that Uniqure NV will post -3.2 EPS for the current fiscal year.

In other Uniqure news, Director Philip Astley-Sparke sold 6,460 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $60.12, for a total transaction of $388,375.20. Following the transaction, the director now owns 12,406 shares in the company, valued at $745,848.72. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $58.38, for a total value of $467,040.00. Following the transaction, the chief executive officer now owns 421,730 shares in the company, valued at approximately $24,620,597.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,460 shares of company stock worth $2,428,395. 2.91% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Harvest Group Wealth Management LLC bought a new position in Uniqure during the first quarter worth about $26,000. Legal & General Group Plc boosted its holdings in Uniqure by 264.2% during the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after buying an additional 700 shares during the last quarter. Pearl River Capital LLC bought a new position in Uniqure during the first quarter worth about $32,000. US Bancorp DE boosted its holdings in Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after buying an additional 427 shares during the last quarter. Finally, Botty Investors LLC bought a new position in Uniqure during the second quarter worth about $78,000. Hedge funds and other institutional investors own 60.51% of the company’s stock.

About Uniqure (NASDAQ:QURE)

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: What are popular green investing opportunities?

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.